Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood

Biomedical Chromatography

Volumn 23, Issue 7, 2009, Pages 707-713

  Hubbard, K Elaine ^a   Schaiquevich, Paula ^a   Bai, Feng ^a   Fraga, Charles H ^a   Miller, Laura ^a   Panetta, John C ^a   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

HPLC; Pharmacokinetics; Topotecan; Whole blood

Indexed keywords

BLOOD; ESTERS;

BLOOD SAMPLES; DETECTION METHODS; FLUORESCENCE DETECTION; HPLC; HPLC METHOD; INDIVIDUALISATION; ITS APPLICATIONS; PLASMA SAMPLES; TOPOTECAN; WHOLE BLOOD;

FLUORESCENCE;

CARBOXYLIC ACID; TOPOTECAN; METHANOL;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; FILTRATION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRECIPITATION; PROCESS OPTIMIZATION; SENSITIVITY AND SPECIFICITY; SPECTRAL SENSITIVITY; VALIDATION PROCESS; BLOOD; CHEMISTRY; DRUG STABILITY; LABORATORY DIAGNOSIS; METHODOLOGY; REPRODUCIBILITY; SPECTROFLUOROMETRY; STATISTICAL MODEL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HUMANS; LINEAR MODELS; METHANOL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; SPECTROMETRY, FLUORESCENCE; TOPOTECAN;

EID: 70149089249     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1173     Document Type: Article

References (20)

1. Bai F, Kirstein MN, Hanna SK, Iacono LC, Johnston B and Stewart CF. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. Journal of Chromatography B Analytical Technologies in the Biomedical Life Sciences 2003; 784: 225-232.
2. Beijnen JH, Smith BR, Keijer WJ, Van Gijn R, Huinink WW, Vlasveld LT, Rodenhuis S and Underberg WJM. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. Journal of Pharmaceutical and Biomedical Analysis 1990; 8: 789-794.
3. D'Argenio DZ and Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource: Los Angeles, CA, 1997.
4. Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Baruchel S and Pratt C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. Journal of Clinical Oncology 2002; 20: 1617-1624.
5. Houghton PJ, Chesire PJ, Myers L, Stewart CF, Synold TW and Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemotherapy and Pharmacology 1992; 31: 229-239.
6. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK and Houghton JA. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemotherapy and Pharmacology 1995; 36: 393-403.
7. Loos WJ, de Bruijn P, Verweij J and Sparreboom A. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography. Anticancer Drugs 2000a; 11: 315-324.
8. Loos WJ, Gelderblom HJ, Verweij J, Brouwer E, de Jonge MJ and Sparreboom A. Gender-dependent pharmacokinetics of topotecan in adult patients. Anticancer Drugs 2000b; 11: 673-680.
9. Metzger ML, Stewart CF, Freeman BB, III, Billups CA, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen EA, Alvarado C, Daw NC and Dome JS. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. Journal of Clinical Oncology 2007; 25: 3130-3136.
10. Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Deporte-Fety R, Bugat R, Canal P and Chatelut E. Individual adaptive dosing of topotecan in ovarian cancer. Clinical Cancer Research 2002; 8: 394-399.
11. Pratt CB, Stewart CF, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L and Meyer WH. Phase I study of topotecan for pediatric patients with malignant solid tumors. Journal of Clinical Oncology 1994; 12: 539-543.
12. Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ and Stewart CF. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clinical Cancer Research 2003; 9: 633-640.
13. Santana VM, Furman WL, Billups CA, Hoffer FA, Davidoff AM, Houghton PJ and Stewart CF. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. Journal of Clinical Oncology 2005; 23: 4039-4047.
14. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr., Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Procedings of the National Academy of Sciences USA 2002; 99: 15387-15392.
15. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR and Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. Journal of Clinical Oncology 1994; 12: 1946-1954.
16. Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ and Gajjar A. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. Journal of Clinical Oncology 2004; 22: 3357-3365.
17. Team RDC. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, 2006.
18. Turner PK, Iacono LC, Panetta JC, Santana VM, Daw NC, Gajjar A and Stewart CF. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemotherapy and Pharmacology 2006; 57: 475-482.
19. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ and Stewart CF. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clinical Cancer Research 1998; 4: 783-789.
20. Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK and Stewart CF. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemotherapy and Pharmacology 1999; 43: 269-276.